GlassScriptPhysician profile
Enrique Ramos
NPI 1477545531
$10,423.74
in general payments reported to CMS, 2019-2025
42 companies · $1,266 in 2025
The $1,266 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,661 · 2020: $1,497 · 2021: $1,435 · 2022: $1,680 · 2023: $1,358 · 2024: $1,528 · 2025: $1,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,151.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,119.59 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $1,046.54 | 2019-2023 | Xarelto |
| Abbvie INC. | $722.79 | 2020-2025 | |
| Horizon Therapeutics Plc | $694.49 | 2019-2023 | Tepezza, Krystexxa |
| Astellas Pharma US INC | $622.19 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $585.72 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Merck Sharp & Dohme LLC | $531.30 | 2019-2025 | Verquvo, Steglatro, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $519.11 | 2021-2025 | |
| Glaxosmithkline, LLC. | $471.36 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Ironwood Pharmaceuticals, INC | $372.78 | 2019-2024 | Linzess |
| Kowa Pharmaceuticals America, INC. | $341.45 | 2019-2025 | Livalo, Zoryve, Seglentis |
| Lilly USA, LLC | $322.73 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Novo Nordisk INC | $301.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.00 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $282.36 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enrique Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.